Comparison Of Pcr/Fish Testing And Next Generation Sequencing (Ngs) In Molecular Diagnosis Of Advanced-Stage Lung Adenocarcinoma.

262Background: As the number of clinically actionable genetic markers for lung adenocarcinoma has increased, the need for accurate and timely identification of these markers has become paramount. In January 2018, our practice began systemically using NGS on all lung adenocarcinoma biopsy specimens. We compared NGS testing to our previous standard (PCR- and FISH-based assays) with regards to breadth of markers tested and time to diagnosis. Methods: We compared detection of mutations in EGFR, ALK, and ROS1 and time from resection or biopsy to test results in recently diagnosed patients from January-March 2018 with stage III/IV adenocarcinoma of the lung to similar patients diagnosed January-December 2016. Results: 63 patients were eligible for analysis: 17 patients in 2018 and 46 patients in 2016. Mean time to diagnosis was 13 days for EGFR, 16 days for ALK and 18 days for ROS1 in 2016, based on previous methods (PCR/FISH) compared to 27 days for EGFR, 26 days for ALK and 26 days for ROS1 in 2018 with NGS t...